Literature DB >> 22961444

Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis.

Anne F Rositch1, Jill Koshiol, Michael G Hudgens, Hilda Razzaghi, Danielle M Backes, Jeanne M Pimenta, Eduardo L Franco, Charles Poole, Jennifer S Smith.   

Abstract

Persistent high-risk human papillomavirus (HR-HPV) infection is the strongest risk factor for high-grade cervical precancer. We performed a systematic review and meta-analysis of HPV persistence patterns worldwide. Medline and ISI Web of Science were searched through January 1, 2010 for articles estimating HPV persistence or duration of detection. Descriptive and meta-regression techniques were used to summarize variability and the influence of study definitions and characteristics on duration and persistence of cervical HPV infections in women. Among 86 studies providing data on over 100,000 women, 73% defined persistence as HPV positivity at a minimum of two time points. Persistence varied notably across studies and was largely mediated by study region and HPV type, with HPV-16, 31, 33 and 52 being most persistent. Weighted median duration of any-HPV detection was 9.8 months. HR-HPV (9.3 months) persisted longer than low-risk HPV (8.4 months), and HPV-16 (12.4 months) persisted longer than HPV-18 (9.8 months). Among populations of HPV-positive women with normal cytology, the median duration of any-HPV detection was 11.5 and HR-HPV detection was 10.9 months. In conclusion, we estimated that approximately half of HPV infections persist past 6 to 12 months. Repeat HPV testing at 12-month intervals could identify women at increased risk of high-grade cervical precancer due to persistent HPV infections.
Copyright © 2012 UICC.

Entities:  

Keywords:  HPV; cervical cancer; clearance; duration; human papillomavirus; literature review; meta-analysis; natural history; persistence; repeat testing; screening

Mesh:

Year:  2012        PMID: 22961444      PMCID: PMC3707974          DOI: 10.1002/ijc.27828

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  110 in total

1.  Explaining heterogeneity in meta-analysis: a comparison of methods.

Authors:  S G Thompson; S J Sharp
Journal:  Stat Med       Date:  1999-10-30       Impact factor: 2.373

Review 2.  HPV infection in adolescents: natural history, complications, and indicators for viral typing.

Authors:  Marcia L Shew; J Dennis Fortenberry
Journal:  Semin Pediatr Infect Dis       Date:  2005-07

3.  Development and duration of human papillomavirus lesions, after initial infection.

Authors:  Rachel L Winer; Nancy B Kiviat; James P Hughes; Diane E Adam; Shu-Kuang Lee; Jane M Kuypers; Laura A Koutsky
Journal:  J Infect Dis       Date:  2005-01-21       Impact factor: 5.226

Review 4.  Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer.

Authors:  Gary M Clifford; Rashida K Rana; Silvia Franceschi; Jennifer S Smith; Gerald Gough; Jeanne M Pimenta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-05       Impact factor: 4.254

5.  Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results.

Authors:  Nubia Muñoz; Fabián Méndez; Héctor Posso; Mónica Molano; Adrian J C van den Brule; Margarita Ronderos; Chris Meijer; Alvaro Muñoz
Journal:  J Infect Dis       Date:  2004-11-22       Impact factor: 5.226

6.  The carcinogenicity of human papillomavirus types reflects viral evolution.

Authors:  Mark Schiffman; Rolando Herrero; Rob Desalle; Allan Hildesheim; Sholom Wacholder; Ana Cecilia Rodriguez; Maria C Bratti; Mark E Sherman; Jorge Morales; Diego Guillen; Mario Alfaro; Martha Hutchinson; Thomas C Wright; Diane Solomon; Zigui Chen; John Schussler; Philip E Castle; Robert D Burk
Journal:  Virology       Date:  2005-06-20       Impact factor: 3.616

7.  A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica.

Authors:  Philip E Castle; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Ana Cecilia Rodriguez; M Concepcion Bratti; Mark E Sherman; Sholom Wacholder; Robert Tarone; Robert D Burk
Journal:  J Infect Dis       Date:  2005-05-02       Impact factor: 5.226

8.  Chlamydia trachomatis infection and persistence of human papillomavirus.

Authors:  Ilvars Silins; Walter Ryd; Anders Strand; Göran Wadell; Sven Törnberg; Bengt Göran Hansson; Xiaohong Wang; Lisen Arnheim; Viktor Dahl; Daniel Bremell; Kenneth Persson; Joakim Dillner; Eva Rylander
Journal:  Int J Cancer       Date:  2005-08-10       Impact factor: 7.396

9.  Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting.

Authors:  Heike Hoyer; Cornelia Scheungraber; Rosemarie Kuehne-Heid; Karin Teller; Christiane Greinke; Sabine Leistritz; Beate Ludwig; Matthias Dürst; Achim Schneider
Journal:  Int J Cancer       Date:  2005-08-10       Impact factor: 7.396

10.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

View more
  69 in total

1.  Association between human papillomavirus and chlamydia trachomatis infection risk in women: a systematic review and meta-analysis.

Authors:  Giulia Naldini; Chiara Grisci; Manuela Chiavarini; Roberto Fabiani
Journal:  Int J Public Health       Date:  2019-06-08       Impact factor: 3.380

2.  The Role of Chlamydia trachomatis in High-Risk Human Papillomavirus Persistence Among Female Sex Workers in Nairobi, Kenya.

Authors:  Nadja Vielot; Michael G Hudgens; Nelly Mugo; Michael Chitwa; Joshua Kimani; Jennifer Smith
Journal:  Sex Transm Dis       Date:  2015-06       Impact factor: 2.830

3.  Human papillomavirus genomics: past, present and future.

Authors:  Ariana Harari; Zigui Chen; Robert D Burk
Journal:  Curr Probl Dermatol       Date:  2014-03-13

Review 4.  Human papillomavirus infection and the multistage carcinogenesis of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

5.  Classical HLA alleles are associated with prevalent and persistent cervical high-risk HPV infection in African women.

Authors:  Sally N Adebamowo; Adebowale A Adeyemo
Journal:  Hum Immunol       Date:  2019-05-06       Impact factor: 2.850

6.  Discrete-time semi-Markov modeling of human papillomavirus persistence.

Authors:  C E Mitchell; M G Hudgens; C C King; S Cu-Uvin; Y Lo; A Rompalo; J Sobel; J S Smith
Journal:  Stat Med       Date:  2011-05-03       Impact factor: 2.373

7.  Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease.

Authors:  David Radley; Alfred Saah; Margaret Stanley
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 8.  Mechanisms of persistence by small DNA tumor viruses.

Authors:  Nathan A Krump; Wei Liu; Jianxin You
Journal:  Curr Opin Virol       Date:  2018-10-01       Impact factor: 7.090

9.  Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults.

Authors:  Daniel C Beachler; Elizabeth A Sugar; Joseph B Margolick; Kathleen M Weber; Howard D Strickler; Dorothy J Wiley; Ross D Cranston; Robert D Burk; Howard Minkoff; Susheel Reddy; Weihong Xiao; Yingshi Guo; Maura L Gillison; Gypsyamber D'Souza
Journal:  Am J Epidemiol       Date:  2014-12-04       Impact factor: 4.897

10.  Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer.

Authors:  S L Sudenga; S Shrestha
Journal:  Int J Infect Dis       Date:  2013-02-27       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.